We continue our series of posts inspired by Drug Hunter’s “Molecules of the Month” (drughunter.com)!
A recently highlighted molecule by Drug Hunter is DNL343 — an oral, CNS-penetrant eIF2B activator, which is now in Phase II/III trials for the treatment of amyotrophic lateral sclerosis (ALS). Exploring the chemical space of this drug candidate's analogs could yield new insights and promising results!
Follow the link to discover the set we’ve prepared for you!
The intracellular protein complex eIF2B regulates protein synthesis and is vital for neuronal health. Modulating the eIF2B function represents a novel and targeted investigational approach in ALS treatment. In neurodegenerative diseases like ALS, neuronal stress suppresses eIF2B activity, leading to impaired protein synthesis and the formation of "stress granules" linked to TDP-43 aggregation, a hallmark of ALS. DNL343 aims to activate eIF2B, recover protein synthesis, disperse TDP-43 aggregates, and enhance neuronal survival.
Use chem-space.com/search to find off-the-shelf and Make-on-Demand molecules of your interest!
